Advanced Research in Anticancer Inhibitors and Targeted Therapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 34
Special Issue Editors
Interests: histone deacetylases (HDACs); YAP signaling; drug resistance in cancer; protein O-GlcNAcylation
Interests: drug discovery; cancer pharmacology; novel molecular targets; herbal medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Rapidly advancing targeted cancer therapy has significantly improved treatment efficacy by selectively inhibiting oncogenic signaling pathways. Among these, histone deacetylase (HDAC) inhibitors, kinase inhibitors, and immune checkpoint inhibitors have demonstrated remarkable potential in both preclinical and clinical studies. However, the emergence of drug resistance, tumor heterogeneity, and adverse side effects pose substantial challenges to their clinical application.
This Special Issue aims to explore novel anticancer inhibitors, their molecular mechanisms, and potential combination strategies to overcome resistance, seeking to provide novel insights into improving the effectiveness and durability of targeted cancer therapies. We welcome original research and review articles focusing on epigenetic therapy, small-molecule inhibitors, immune-based treatments, and new therapeutic targets. Studies employing biochemical, molecular, and cellular approaches to investigate drug efficacy, biomarker discovery, and resistance mechanisms are highly encouraged.
Dr. Changmin Peng
Dr. Hassan Ebrahim
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- histone deacetylases (HDACs)
- YAP signaling
- targeted therapy
- oncogenic signaling
- biomarker discovery
- small-molecule inhibitors
- cancer drug resistance
- epigenetic therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
